Cost-Effectiveness of Tdap Vaccination of Adults Aged ≥65 Years in the Prevention of Pertussis in the US: A Dynamic Model of Disease Transmission
View/ Open
Author
McGarry, Lisa J.
Krishnarajah, Girishanthy
Hill, Gregory
Masseria, Cristina
Skornicki, Michelle
Pruttivarasin, Narin
Arondekar, Bhakti
Roiz, Julie
Pelton, Stephen I.
Published Version
https://doi.org/10.1371/journal.pone.0072723Metadata
Show full item recordCitation
McGarry, Lisa J., Girishanthy Krishnarajah, Gregory Hill, Cristina Masseria, Michelle Skornicki, Narin Pruttivarasin, Bhakti Arondekar, Julie Roiz, Stephen I. Pelton, and Milton C. Weinstein. 2014. “Cost-Effectiveness of Tdap Vaccination of Adults Aged ≥65 Years in the Prevention of Pertussis in the US: A Dynamic Model of Disease Transmission.” PLoS ONE 9 (1): e72723. doi:10.1371/journal.pone.0072723. http://dx.doi.org/10.1371/journal.pone.0072723.Abstract
Objectives: In February 2012, the Advisory Committee on Immunization Practices (ACIP) advised that all adults aged ≥65 years receive a single dose of reduced-antigen-content tetanus, diphtheria, and acellular pertussis (Tdap), expanding on a 2010 recommendation for adults >65 that was limited to those with close contact with infants. We evaluated clinical and economic outcomes of adding Tdap booster of adults aged ≥65 to “baseline” practice [full-strength DTaP administered from 2 months to 4–6 years, and one dose of Tdap at 11–64 years replacing decennial Td booster], using a dynamic model. Methods: We constructed a population-level disease transmission model to evaluate the cost-effectiveness of supplementing baseline practice by vaccinating 10% of eligible adults aged ≥65 with Tdap replacing the decennial Td booster. US population effects, including indirect benefits accrued by unvaccinated persons, were estimated during a 1-year period after disease incidence reached a new steady state, with consequences of deaths and long-term pertussis sequelae projected over remaining lifetimes. Model outputs include: cases by severity, encephalopathy, deaths, costs (of vaccination and pertussis care) and quality-adjusted life-years (QALYs) associated with each strategy. Results in terms of incremental cost/QALY gained are presented from payer and societal perspectives. Sensitivity analyses vary key parameters within plausible ranges. Results: For the US population, the intervention is expected to prevent >97,000 cases (>4,000 severe and >5,000 among infants) of pertussis annually at steady state. Additional vaccination costs are $4.7 million. Net cost savings, including vaccination costs, are $47.7 million (societal perspective) and $44.8 million (payer perspective). From both perspectives, the intervention strategy is dominant (less costly, and more effective by >3,000 QALYs) versus baseline. Results are robust to sensitivity analyses and alternative scenarios. Conclusions: Immunization of eligible adults aged ≥65, consistent with the current ACIP recommendation, is cost saving from both payer and societal perspectives.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886978/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879488
Collections
- HMS Scholarly Articles [17918]
- SPH Scholarly Articles [6362]
Contact administrator regarding this item (to report mistakes or request changes)